Table 4.

AEs experienced in primary cohort regardless of attribution

AE*Patients with AEs of any gradePatients with AEs grade 3 to 4
No.%No.%
Hematologic laboratory event     
 Anemia 67 33 
 Thrombocytopenia 33 22 
 Leukopenia 33 11 
 Lymphopenia 33 22 
 Decreased WBCs 22 22 
Nonhematologic laboratory event     
 Increased aspartate aminotransferase (AST) 33 
 Hyperglycemia 33 22 
 Hyperuricemia 33 11 
 Hypoalbuminemia 33 
 Increased alkaline phosphatase (ALP) 22 
 Hypocalcemia 22 
 Hypernatremia 22 
Clinical event     
 Cough 56 
 Fatigue 56 
 Dyspnea 44 11 
 Chest pain 33 
 Diarrhea 33 
 Dizziness 33 
 Fever 33 
 Headache 33 11 
 Nausea 33 
 Weakness 33 11 
 Blurred vision 22 
 Constipation 22 
 Dyspepsia 22 
 Productive cough 22 
 Rash 22 
 Sore throat 22 
 Upper respiratory infection 22 
 Weight loss 22 
AE*Patients with AEs of any gradePatients with AEs grade 3 to 4
No.%No.%
Hematologic laboratory event     
 Anemia 67 33 
 Thrombocytopenia 33 22 
 Leukopenia 33 11 
 Lymphopenia 33 22 
 Decreased WBCs 22 22 
Nonhematologic laboratory event     
 Increased aspartate aminotransferase (AST) 33 
 Hyperglycemia 33 22 
 Hyperuricemia 33 11 
 Hypoalbuminemia 33 
 Increased alkaline phosphatase (ALP) 22 
 Hypocalcemia 22 
 Hypernatremia 22 
Clinical event     
 Cough 56 
 Fatigue 56 
 Dyspnea 44 11 
 Chest pain 33 
 Diarrhea 33 
 Dizziness 33 
 Fever 33 
 Headache 33 11 
 Nausea 33 
 Weakness 33 11 
 Blurred vision 22 
 Constipation 22 
 Dyspepsia 22 
 Productive cough 22 
 Rash 22 
 Sore throat 22 
 Upper respiratory infection 22 
 Weight loss 22 
*

All AEs that occurred in at least 2 treated patients.

Close Modal

or Create an Account

Close Modal
Close Modal